Ascendis Pharma (ASND) Study result presentation summary

Study design and participant characteristics

• Phase 2 PaTH Forward trial evaluated palopegteriparatide in adults with chronic hypoparathyroidism, including a 4-week randomized, double-blind, placebo-controlled period followed by an open-label extension up to 266 weeks.

• 59 participants enrolled; mean age 50 years, 81% female, 92% White, with most cases acquired from neck surgery.

Efficacy outcomes

• 93% of participants were independent from conventional therapy (no active vitamin D, ≤600 mg/day calcium) at week 214.

• 98% maintained normal serum calcium at week 214; mean 24-hour urine calcium normalized within 26 weeks.

• Bone turnover markers (CTX and P1NP) and bone mineral density (BMD) scores remained stable and within normal ranges through week 214.

Renal function outcomes

• Mean eGFR increased by approximately 9.6 mL/min/1.73m² from baseline and was sustained through week 214.

• 67.8% of participants had a clinically meaningful ≥5 mL/min/1.73m² increase in eGFR at week 214.